Integra LifeSciences Holdings (IART)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $1.12B
Last updated: Nov 17, 2026 at 11:06 AM ET
Integra LifeSciences Holdings (IART) Financials: Revenue, Profit and Cash Flow
Integra LifeSciences Holdings reported revenue of $1.64B for the fiscal year ended Dec 31, 2025, up 1.5% from the year before. That year, net income was -$516.47M with a net margin of -31.6%, operating cash flow was $50.38M and free cash flow was -$31.05M. The quarter ended Sep 30, 2026 had revenue of $411.18M and net income of $14.85M.
Revenue and Margins
The operating margin was -30.2% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $992.08M, a compound annual rate of 5.7%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1.64B | +1.5% | 50.9% | -30.2% | -31.6% |
| Dec 2024 | $1.61B | +4.5% | 54.8% | 1.8% | -0.4% |
| Dec 2023 | $1.54B | -1.0% | 57.4% | 7.2% | 4.4% |
| Dec 2022 | $1.56B | +1.0% | 62.3% | 15.3% | 11.6% |
| Dec 2021 | $1.54B | +12.4% | 61.2% | 12.8% | 11.0% |
| Dec 2020 | $1.37B | -9.6% | 62.0% | 11.0% | 9.8% |
| Dec 2019 | $1.52B | +3.1% | 62.8% | 6.2% | 3.3% |
| Dec 2018 | $1.47B | +23.9% | 61.2% | 7.5% | 4.1% |
| Dec 2017 | $1.19B | +19.8% | 63.3% | 3.8% | 5.4% |
| Dec 2016 | $992.08M | N/A | 64.8% | 11.6% | 7.5% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.64B | $1.61B | $1.54B | $1.56B | $1.54B | $1.37B | $1.52B | $1.47B | $1.19B | $992.08M |
| Cost of revenue | $803.63M | $728.47M | $656.84M | $587.36M | $597.81M | $520.83M | $564.68M | $571.50M | $435.51M | $349.09M |
| Gross profit | $831.62M | $882.06M | $884.74M | $970.31M | $944.64M | $851.03M | $952.88M | $900.95M | $752.73M | $642.99M |
| Research and development | $98.97M | $115.38M | $104.19M | $101.19M | $93.05M | $77.38M | $144.49M | $78.04M | $63.45M | $58.16M |
| Operating income | -$493.37M | $28.41M | $111.53M | $238.92M | $197.23M | $151.37M | $93.76M | $111.00M | $44.80M | $115.34M |
| Net income | -$516.47M | -$6.94M | $67.74M | $180.55M | $169.07M | $133.89M | $50.20M | $60.80M | $64.74M | $74.56M |
| EBITDA | -$338.28M | $178.84M | $244.92M | $376.71M | $378.17M | $283.91M | $218.13M | $236.29M | $137.82M | $191.38M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $411.18M | $418.76M | $391.92M | $434.93M | $402.06M | $415.61M | $382.65M | $442.65M | $380.83M | $418.18M | $368.87M | $397.04M |
| Gross profit | $209.87M | $219.74M | $216.98M | $220.87M | $206.99M | $209.33M | $194.43M | $249.07M | $200.24M | $225.92M | $206.83M | $226.49M |
| Operating income | $18.90M | $19.29M | $11.47M | $23.04M | $11.76M | -$512.67M | -$15.50M | $35.63M | -$8.15M | -$3.03M | $3.96M | $36.05M |
| Net income | $14.85M | $4.48M | -$4.62M | -$1.70M | -$5.40M | -$484.07M | -$25.29M | $19.43M | -$10.70M | -$12.40M | -$3.28M | $19.83M |
Balance Sheet
As of Dec 2025, total debt of $1.86B exceeded cash and equivalents by $1.62B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.60B | $4.04B | $3.78B | $3.89B | $3.78B | $3.62B | $3.30B | $3.11B | $3.21B | $1.81B |
| Current assets | $1.16B | $1.08B | $1.06B | $1.16B | $1.15B | $1.24B | $858.17M | $775.08M | $822.15M | $495.17M |
| Cash and equivalents | $235.05M | $246.38M | $276.40M | $456.66M | $513.45M | $470.17M | $198.91M | $138.84M | $174.94M | $102.06M |
| Total liabilities | $2.56B | $2.49B | $2.19B | $2.09B | $2.10B | $2.10B | $1.89B | $1.73B | $2.25B | $968.29M |
| Short-term debt | $126.55M | $607.08M | $14.53M | $38.13M | $45.00M | $146.25M | $45.00M | $22.50M | $82.79M | $0 |
| Long-term debt | $1.73B | $1.20B | $1.49B | $1.41B | $1.50B | $1.41B | $1.30B | $1.33B | $1.78B | $665.00M |
| Shareholder equity | $1.04B | $1.55B | $1.59B | $1.80B | $1.68B | $1.51B | $1.42B | $1.38B | $962.31M | $839.67M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.51B | $3.56B | $3.58B | $3.60B | $3.65B | $3.67B | $4.05B | $4.04B | $4.07B | $4.07B | $4.08B | $3.78B |
| Total liabilities | $2.44B | $2.52B | $2.54B | $2.56B | $2.61B | $2.63B | $2.53B | $2.49B | $2.54B | $2.54B | $2.48B | $2.19B |
| Cash and equivalents | $252.26M | $214.41M | $236.81M | $235.05M | $232.19M | $217.91M | $239.10M | $246.38M | $215.16M | $215.24M | $591.91M | $276.40M |
| Shareholder equity | $1.07B | $1.04B | $1.04B | $1.04B | $1.04B | $1.04B | $1.52B | $1.55B | $1.52B | $1.53B | $1.60B | $1.59B |
Cash Flow
In the fiscal year ended Dec 2025, capital expenditures exceeded operating cash flow, leaving negative free cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $50.38M | $129.38M | $139.96M | $264.47M | $312.43M | $203.83M | $231.43M | $199.68M | $114.54M | $116.41M |
| Capital expenditures | $81.44M | $104.42M | $66.86M | $42.34M | $48.02M | $38.89M | $69.54M | $77.74M | $43.50M | $47.33M |
| Free cash flow | -$31.05M | $24.96M | $73.09M | $222.13M | $264.40M | $164.94M | $161.90M | $121.94M | $71.04M | $69.08M |
| Dividends paid | N/A | N/A | $93.24M | $5.46M | $2.02M | $44.56M | $434.00K | N/A | $0 | $0 |
| Share repurchases | $221.00K | $52.47M | $275.00M | $125.00M | $0 | $100.00M | $0 | $0 | N/A | N/A |
| Investing cash flow | -$108.06M | -$390.81M | -$94.18M | -$58.58M | -$161.44M | -$68.07M | -$162.67M | -$49.70M | -$1.22B | -$42.62M |
| Financing cash flow | $28.34M | $237.86M | -$229.93M | -$251.95M | -$98.23M | $121.63M | -$8.77M | -$180.87M | $1.17B | -$15.12M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $95.98M | $22.80M | $9.80M | $11.82M | $40.91M | $8.92M | -$11.26M | $50.74M | $22.48M | $40.40M | $15.76M | $58.75M |
| Capital expenditures | $10.25M | $12.31M | $14.85M | $17.21M | $15.16M | $20.15M | $28.92M | $29.60M | $29.65M | $29.71M | $15.46M | $24.54M |
| Free cash flow | $85.73M | $10.49M | -$5.04M | -$5.40M | $25.75M | -$11.23M | -$40.18M | $21.14M | -$7.16M | $10.69M | $291.00K | $34.22M |
Frequently Asked Questions About IART
What is Integra LifeSciences Holdings' annual revenue?
Integra LifeSciences Holdings reported revenue of $1.64B for the fiscal year ended Dec 31, 2025.
How fast is Integra LifeSciences Holdings' revenue growing?
Revenue was up 1.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 1.6%.
Is Integra LifeSciences Holdings profitable?
No. Integra LifeSciences Holdings reported net income of -$516.47M for the fiscal year ended Dec 31, 2025, with a net margin of -31.6%.
How much free cash flow does IART generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $50.38M minus capital expenditures of $81.44M produced free cash flow of -$31.05M.
How much debt does Integra LifeSciences Holdings have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $1.73B, short-term debt of $126.55M and cash and equivalents of $235.05M.
IART pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors